Last updated: 3 June 2024 at 4:56pm EST

Avery Catlin Net Worth




The estimated Net Worth of Avery W Catlin is at least $1.42 million dollars as of 11 May 2017. Mr. Catlin owns over 5,000 units of Provention Bio stock worth over $1,174,060 and over the last 16 years he sold PRVB stock worth over $0. In addition, he makes $246,366 as Independent Director at Provention Bio.

Mr. Catlin PRVB stock SEC Form 4 insiders trading

Avery has made over 18 trades of the Provention Bio stock since 2009, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of PRVB stock worth $30,750 on 11 May 2017.

The largest trade he's ever made was exercising 183,333 units of Provention Bio stock on 6 December 2013 worth over $1,495,997. On average, Avery trades about 8,689 units every 60 days since 2009. As of 11 May 2017 he still owns at least 47,000 units of Provention Bio stock.

You can see the complete history of Mr. Catlin stock trades at the bottom of the page.





Avery Catlin biography

Avery W. Catlin CPA serves as Independent Director of the Company. He currently serves on the Board of Corbus Pharmaceutical Holdings, Inc. Mr. Catlin previously served as Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc., where he raised more than $500 million from equity, convertible debt and private placement transactions, as well as devised and led financial strategies to successfully complete several asset acquisitions. Prior to Celldex, Mr. Catlin held senior financial and operational positions with biopharma companies Endogen, Inc. and Repligen Corporation. Mr. Catlin earned a B.A. in Psychology from the University of Virginia and an MBA from Babson College. He is also a certified public accountant. Mr. Catlin’s more than 22 years of experience as a senior financial officer of public biopharmaceutical companies make him a valuable member of our board of directors.

What is the salary of Avery Catlin?

As the Independent Director of Provention Bio, the total compensation of Avery Catlin at Provention Bio is $246,366. There are 13 executives at Provention Bio getting paid more, with Ashleigh Palmer having the highest compensation of $3,959,460.



How old is Avery Catlin?

Avery Catlin is 72, he's been the Independent Director of Provention Bio since 2018. There are no older and 17 younger executives at Provention Bio.

What's Avery Catlin's mailing address?

Avery's mailing address filed with the SEC is C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062.

Insiders trading at Provention Bio

Over the last 6 years, insiders at Provention Bio have traded over $81,606,241 worth of Provention Bio stock and bought 165,475 units worth $1,543,065 . The most active insiders traders include Capital (Master), L.P.Sessa..., Nancy Wysenski et Avery W Catlin. On average, Provention Bio executives and independent directors trade stock every 35 days with the average trade being worth of $3,621,900. The most recent stock trade was executed by Capital (Master), L.P.Sessa... on 14 April 2023, trading 2,190,549 units of PRVB stock currently worth $53,274,152.



What does Provention Bio do?

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.



What does Provention Bio's logo look like?

Provention Bio, Inc. logo

Complete history of Mr. Catlin stock trades at Celldex Therapeutics, Corbus Pharmaceuticals Inc et Provention Bio

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
11 May 2017 Avery W Catlin
Acheter 5,000 $6.15 $30,750
11 May 2017
47,000
22 Nov 2016 Avery W Catlin
Acheter 2,000 $7.55 $15,100
22 Nov 2016
42,000
18 Aug 2015 Avery W Catlin
Acheter 8,212 $1.90 $15,603
18 Aug 2015
40,000
17 Aug 2015 Avery W Catlin
Acheter 11,788 $1.94 $22,869
17 Aug 2015
31,788
9 Jun 2015 Avery W Catlin
Acheter 20,000 $3.10 $62,000
9 Jun 2015
20,000
2 Sep 2016 Avery W Catlin
Sr. VP et Directeur des finances
Exercice d'option 10,000 $2.80 $28,000
2 Sep 2016
83,586
3 Jun 2016 Avery W Catlin
Sr. VP et Directeur des finances
Exercice d'option 22,847 $3.01 $68,769
3 Jun 2016
73,586
3 Jun 2016 Avery W Catlin
Sr. VP et Directeur des finances
Exercice d'option 22,847 $3.01 $68,769
3 Jun 2016
73,586
9 Mar 2016 Avery W Catlin
Sr. VP et Directeur des finances
Exercice d'option 15,000 $2.80 $42,000
9 Mar 2016
50,739
9 Mar 2016 Avery W Catlin
Sr. VP et Directeur des finances
Exercice d'option 15,000 $2.80 $42,000
9 Mar 2016
50,739
23 Nov 2015 Avery W Catlin
Sr. VP et Directeur des finances
Exercice d'option 25,000 $8.52 $213,000
23 Nov 2015
60,109
11 Sep 2015 Avery W Catlin
Sr. VP et Directeur des finances
Exercice d'option 10,000 $4.50 $45,000
11 Sep 2015
35,109
15 Jun 2015 Avery W Catlin
Sr. VP et Directeur des finances
Exercice d'option 25,000 $8.52 $213,000
15 Jun 2015
49,609
8 Sep 2014 Avery W Catlin
Sr. VP et Directeur des finances
Exercice d'option 10,000 $4.50 $45,000
8 Sep 2014
24,609
6 Dec 2013 Avery W Catlin
Sr. VP et Directeur des finances
Exercice d'option 183,333 $8.16 $1,495,997
6 Dec 2013
197,442
9 Aug 2011 Avery W Catlin
Sr. VP et Directeur des finances
Acheter 2,000 $2.39 $4,780
9 Aug 2011
2,000
8 Sep 2010 Avery W Catlin
Sr. VP et Directeur des finances
Acheter 2,000 $3.51 $7,020
8 Sep 2010
2,000
30 Nov 2009 Avery W Catlin
Sr. VP et Directeur des finances
Acheter 1,000 $4.41 $4,410
30 Nov 2009
1,000


Provention Bio executives and stock owners

Provention Bio executives and other stock owners filed with the SEC include: